Healthcare Professional Portal
Healthcare Professional Portal
The first in our 2026 Beyond sleepless nights: managing chronic insomnia in adults webinar series, in collaboration with MIMS Learning.
Join Dr Zoe Schaedel, GP and menopause specialist, as she discusses the impact of chronic insomnia on working women experiencing menopause. Dr. Schaedel will go through findings from a brand new study “Insomnia Disorder in Midlife Women” exploring the impact persistent sleep loss can have in the workplace, including concentration, performance, mental health and working hours.
MIMS WEBINAR SERIES
Join us for this MIMS Learning webinar series focusing on chronic insomnia in adults. Over five webinars throughout 2026, our expert speakers will explore the impact of chronic insomnia in diverse patient populations and discuss diagnostic approaches.
They will also highlight recommendations for chronic insomnia management in clinical practice, including pharmacological interventions such as QUVIVIQ®▼ (daridorexant), as well as lifestyle and psychological approaches.
Click the button below to find out more and register via MIMS Learning:
One of our product specialists would be happy to answer your questions.
QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated June 2024. Accessed July 2024.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
This information is intended for UK Healthcare Professionals only.
By entering this site you are confirming that you are a UK Healthcare Professional.
UK-DA-00217 | Date of preparation: February 2026
Dr Zoe Schaedel is an NHS GP and menopause specialist with a special interest in both sleep medicine and women’s health.
Dr Schaedel lectures widely on the topic of sleep and has taught on the International Sleep Medicine Course. She sits on the British Sleep Society Education Committee and the British Menopause Society (BMS) Medical Advisory Committee.
Dr Schaedel is the co-founder of The Good Sleep Clinic, which specialises in non-pharmacological treatment of insomnia, and is the co-director of Myla Health, a private women’s health clinic. Dr Schaedel has published articles on the topics of menopause and sleep in the Lancet and Post Reproductive Health and has featured in publications including The Guardian, The Daily Express, Grazia, Stylist and Good Housekeeping.
You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)
UK-DA-00439 | Date of preparation: February 2026
You are being redirected to our partner’s website pro.idorsia.uk.
The content of this website contains promotional information for UK healthcare professionals and is managed by Idorsia Pharmaceuticals UK Ltd.
UK-DA-01463 | Date of preparation: April 2026
Your resource is ready to download.
Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.
Download will open in a new window.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
UK-DA-00445 | Date of preparation: Februrary 2026
Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.
It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.
For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.
You already have an account?
Register to get access to:
